[{"id":"94c5955f-8283-4ecf-ba19-c80d9a7540f8","acronym":"TAR-200-101","url":"https://clinicaltrials.gov/study/NCT02722538","created_at":"2021-01-18T13:19:14.253Z","updated_at":"2024-07-02T16:35:36.803Z","phase":"Phase 1b","brief_title":"Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT02722538 - TAR-200-101","lead_sponsor":"Taris Biomedical LLC","biomarkers":" PD-L1 • CD8 • CD4 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CD4 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Inlexzo (gemcitabine intravesical system)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 05/31/2016","start_date":" 05/31/2016","primary_txt":" Primary completion: 05/02/2019","primary_completion_date":" 05/02/2019","study_txt":" Completion: 05/02/2019","study_completion_date":" 05/02/2019","last_update_posted":"2023-09-18"},{"id":"faea8229-90b5-43f1-829f-e4b604965cd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02720367","created_at":"2021-01-18T13:18:32.264Z","updated_at":"2024-07-02T16:36:48.991Z","phase":"Phase 1b","brief_title":"Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT02720367","lead_sponsor":"Taris Biomedical LLC","biomarkers":" CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Inlexzo (gemcitabine intravesical system)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-03-10"}]